Voriconazole Therapeutic Drug Monitoring: How to Adjust the Dose in Pediatrics?

Toktam Faghihi; Miia Tiihonen

doi:10.5812/ijp.111582

Voriconazole Therapeutic Drug Monitoring: How to Adjust the Dose in Pediatrics?

authors:

Toktam Faghihi ^{1
, 2
, *} , Miia Tiihonen ³

1 Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

2 Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

3 School of Pharmacy, University of Eastern Finland, Kuopio, Finland

Iranian Journal of Pediatrics: Vol.31, issue 2; e111582

published online: April 27, 2021

article type: Letter

received: December 12, 2020

revised: January 30, 2021

accepted: March 5, 2021

DOI: https://doi.org/10.5812/ijp.111582

how to cite: Faghihi T, Tiihonen M. Voriconazole Therapeutic Drug Monitoring: How to Adjust the Dose in Pediatrics?. Iran J Pediatr. 2021;31(2):e111582. https://doi.org/10.5812/ijp.111582.

Keywords

Children Voriconazole Therapeutic Drug Monitoring

Footnotes

Authors' Contribution: Toktam Faghihi: Study concept and design, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. Miia Tiihonen: Critical revision of the manuscript for important intellectual content.
Conflict of Interests: There is no conflict of interest.
Funding/Support: Tehran University of Medical Sciences funded the study.

References

1.
John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15(11):881-95. [PubMed ID: 31550939]. https://doi.org/10.1080/17425255.2019.1671971.
2.
Ashley ED, Perfect JR. Pharmacology of azoles. Up to date; 2020, [updated Jul 30, 2020]. Available from: https://www.uptodate.com/contents/pharmacology-of-azoles.
3.
Chen K, Zhang X, Ke X, Du G, Yang K, Zhai S. Individualized medication of voriconazole: A practice guideline of the division of therapeutic drug monitoring, chinese pharmacological society. Ther Drug Monit. 2018;40(6):663-74. [PubMed ID: 30192314]. [PubMed Central ID: PMC6250289]. https://doi.org/10.1097/FTD.0000000000000561.
4.
Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032-42. [PubMed ID: 22430956]. [PubMed Central ID: PMC3370730]. https://doi.org/10.1128/AAC.05761-11.
5.
Up to Date. Section on voriconazole monograph in pediatrics. 2020. Available from: https://www.uptodate.com.
6.
Kang HM, Lee HJ, Cho EY, Yu KS, Lee H, Lee JW, et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr Hematol Oncol. 2015;32(8):557-67. [PubMed ID: 26558811]. https://doi.org/10.3109/08880018.2015.1088905.
7.
Perreault S, McManus D, Anderson A, Lin T, Ruggero M, Topal JE. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies. J Oncol Pharm Pract. 2019;25(6):1305-11. [PubMed ID: 29996736]. https://doi.org/10.1177/1078155218786028.
8.
Palmisani E, Barco S, Cangemi G, Moroni C, Dufour C, Castagnola E. Need of voriconazole high dosages, with documented cerebrospinal fluid penetration, for treatment of cerebral aspergillosis in a 6-month-old leukaemic girl. J Chemother. 2017;29(1):42-4. [PubMed ID: 25748533]. https://doi.org/10.1179/1973947815Y.0000000009.

comments